Website and marketing claims

What FDA warning letters often say about website and marketing claims

FDA reviewers often cite public web pages, social media, product labels, and online sales paths when they explain warning-letter findings.

Recent letters show a practical pattern: FDA reads the public record around a product. The agency may cite the product page, a blog post, a social profile, an e-commerce listing, a label shown online, or a claim that points buyers toward checkout.

Dietary supplement example

In the OptiHealth Products letter, FDA quoted website and Facebook language about disease-related benefits for a supplement product. The letter tied those statements to intended use and misbranding issues.

Tobacco e-commerce example

In the swisschlz.com letter, FDA said nicotine pouch products were offered for sale or distribution to U.S. customers and lacked required marketing authorization. The site itself was central to the finding.

Animal drug example

In The Fish Aid letter, FDA cited an online store that sold animal drug products for aquarium fish and birds. The letter quoted labels and website statements about treatment of bacterial infections.

Reader takeaway

Marketing copy, educational content, social posts, labels, and purchase paths can appear in the same FDA narrative. A public-facing claim may matter even when the brand sees it as content rather than a compliance document.

Sources

This article is public-source monitoring. It is not legal or regulatory advice.